About GALAXY MEDICARE LIMITED
Incorporated in July 1992, Galaxy Medicare Limited is a healthcare-focused company engaged in the manufacturing and export of medical devices, plaster of Paris (POP) bandages, and surgical dressings. The company uses premium-grade raw materials sourced from trusted vendors to ensure superior quality products.
Galaxy Medicare offers a diverse product portfolio that includes surgical dressings, adhesive tapes, POP bandages, compression bandages, orthopedic solutions, and wound care products. These products are marketed under flagship brands such as POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE, GYPSONET, GYPSOCHLOR, and FIXCAN.
The company operates through multiple business models:
Manufacturing & Branding for in-house brands.
OEM Services including sourcing, design, and quality testing for other brand owners.
Institutional Sales through government tenders on the GEM Portal.
Exports of medical products across international markets.
With 27 registered trademarks in India, Galaxy Medicare has established strong domestic and global market presence. Its products are widely accepted by the medical community and supplied to government health departments, private hospitals, and corporate healthcare institutions.
The company also holds ISO 9001:2015 and ISO 13485:2016 certifications, ensuring compliance with stringent international quality standards. As of March 2025, the company employs 190 professionals across various departments.
Why To Invest in GALAXY MEDICARE LIMITED
Strong Market Presence – With over three decades of operations and 27 registered trademarks, the company has established credibility in the Indian and international medical device industry.
Diverse Product Portfolio – Galaxy Medicare offers a wide range of surgical and wound care solutions, catering to both domestic and export markets.
Financial Performance – Although profit after tax saw a slight dip in FY25, revenue has shown consistent growth with a CAGR of around 9%.
Healthy Ratios – The company reported an ROE of 19.88% and ROCE of 22.38% in FY25, reflecting efficient capital utilization.
Reduced Debt Levels – Total borrowings have declined from Rs. 9.15 crore in FY23 to Rs. 4.61 crore in FY25, showing stronger financial stability.
Objects of the Issue – Proceeds will be utilized for capital expenditure, working capital, and general corporate purposes, which may further strengthen its business operations.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 31.49 | 32.53 | 32.31 |
| Total Income | 40.27 | 36.94 | 32.03 |
| Profit After Tax | 3.37 | 3.71 | 1.57 |
| EBITDA | 4.58 | 5.26 | 3.14 |
| NET Worth | 18.36 | 15.54 | 11.94 |
| Reserves and Surplus | 12.29 | 12.29 | 14.78 |
| Total Borrowing | 4.61 | 8.12 | 9.15 |
Explore Other Products
